BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32923264)

  • 21. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
    Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and treatment of hereditary angioedema.
    Canonica GW; Rossi O
    Panminerva Med; 2012 Sep; 54(3):241-53. PubMed ID: 22801442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency.
    Zanichelli A; Mansi M; Periti G; Cicardi M
    Expert Rev Clin Immunol; 2013 May; 9(5):477-88. PubMed ID: 23634741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Guidelines for the diagnosis and treatment of hereditary angioedema].
    Marković AS; Rozmanić V; Anić B; Aberle N; Racić G; Novak S; Sunara D; Grdinić B; Karadza-Lapić L; Radas MR; Karanović B; Kvenić B
    Lijec Vjesn; 2014; 136(5-6):117-29. PubMed ID: 25154179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy.
    Farkas H; Jakab L; Temesszentandrási G; Visy B; Harmat G; Füst G; Széplaki G; Fekete B; Karádi I; Varga L
    J Allergy Clin Immunol; 2007 Oct; 120(4):941-7. PubMed ID: 17761272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
    Piras V; Alves F; Gonçalo M
    Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
    Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema.
    Henry Li H; Riedl M; Kashkin J
    Clin Rev Allergy Immunol; 2019 Apr; 56(2):207-218. PubMed ID: 29909591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.
    Bork K
    Immunotherapy; 2014; 6(5):533-51. PubMed ID: 24635050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel pathogenetic factor of laryngeal attack in hereditary angioedema? Involvement of protease activated receptor 1.
    Farkas H; Máj C; Kenessey I; Sebestyén A; Krencz I; Pápay J; Cervenak L
    Allergy Asthma Clin Immunol; 2022 Jul; 18(1):60. PubMed ID: 35787812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Therapies for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review of Current Evidence.
    Riha HM; Summers BB; Rivera JV; Van Berkel MA
    J Emerg Med; 2017 Nov; 53(5):662-679. PubMed ID: 28939396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fresh frozen plasma for the treatment of hereditary angioedema.
    Prematta M; Gibbs JG; Pratt EL; Stoughton TR; Craig TJ
    Ann Allergy Asthma Immunol; 2007 Apr; 98(4):383-8. PubMed ID: 17458436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evidence based therapeutic approach to hereditary and acquired angioedema.
    Bork K
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hereditary angioedema attack: what happens to vasoactive mediators?
    Ferrara AL; Bova M; Petraroli A; Veszeli N; Galdiero MR; Braile M; Marone G; Cristinziano L; Marcella S; Modestino L; Farkas H; Loffredo S
    Int Immunopharmacol; 2020 Jan; 78():106079. PubMed ID: 31841756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hereditary angioedema: epidemiology, management, and role of icatibant.
    Ghazi A; Grant JA
    Biologics; 2013; 7():103-13. PubMed ID: 23662043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.
    Hakl R; Kuklínek P; Krčmová I; Králíčková P; Freiberger T; Janků P; Vlková M; Litzman J
    J Clin Immunol; 2018 Oct; 38(7):810-815. PubMed ID: 30280305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency.
    Bork K; Hardt J; Witzke G
    J Allergy Clin Immunol; 2012 Sep; 130(3):692-7. PubMed ID: 22841766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor.
    McKibbin L; Barber C; Kalicinsky C; Warrington R
    Allergy Asthma Clin Immunol; 2019; 15():66. PubMed ID: 31749860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
    Gower RG; Lumry WR; Davis-Lorton MA; Johnston DT; Busse PJ
    Allergy Asthma Proc; 2012; 33(3):235-40. PubMed ID: 22584192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chapter 22: Hereditary and acquired angioedema.
    Georgy MS; Pongracic JA
    Allergy Asthma Proc; 2012; 33 Suppl 1():73-76. PubMed ID: 22794695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.